Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2002-08-21
2008-09-02
Canella, Karen A. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S007100, C436S544000
Reexamination Certificate
active
07419777
ABSTRACT:
This invention provides methods for determining or predicting response to cancer therapy in an individual using differential image analysis of immunohistochemically stained tumor samples.
REFERENCES:
patent: 5288477 (1994-02-01), Bacus
patent: 5536642 (1996-07-01), Barbera-Guillem et al.
patent: 2001/0044124 (2001-11-01), Bacus
patent: 2001/0049114 (2001-12-01), Bacus
patent: 2000-515964 (2000-11-01), None
patent: WO 96/17873 (1996-06-01), None
patent: WO 99/41613 (1999-08-01), None
patent: WO 99/53953 (1999-10-01), None
patent: WO 01/25473 (2001-04-01), None
patent: WO 01/51924 (2001-07-01), None
patent: WO 01/51928 (2001-07-01), None
Heinrich et al (Blood, Aug. 2000, vol. 96, pp. 925-932).
Landuzzi et al (American Journal of Pathology, Dec. 2000, vol. 157, pp. 2123-2131).
Schlom (‘Monoclonal Antibodies: They're More and Less Than You Think’, In: Molecular Foundations of Oncology, S. Broader, Ed, 1991, pp. 95-134).
Arteaga et al., “p185c-erbβ-2Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association between an Oncogenic Receptor Tyrosine Kinase and Drug-Induced DNA Repair,” Cancer Res., 54:3758-3765, 1994.
Bacus et al., “Potential Use of Image Analysis for the Evaluation of Cellular Predicting Factors for Therapeutic Response in Breast Cancers,” Anal. Quant. Cytol. Histol., 19:316-328, 1997.
Cantley and Neel, “New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositude 3-kinase/AKT pathway,” Proc. Natl. Acad. Sci. U.S.A., 96:4240-45, 1999.
Chui et al., “Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues,” British J. of Cancer, 73:1233-1236, 1996.
Cobleigh et al., “Mutinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease,” J. Clin. Oncol., 17:2639-2648, 1999.
Datta et al., “Cellular survival: a play in three Akts,” Genes and Dev., 13:2905-27, 1999.
DiGiovanna, “Clinical Significance of HER-2
eu Overexpression: Part I,” PPO Updates: Princ. Practice Oncol., 13:1-9, 1999.
Hancock et al., “A Monoclonal Antidoby against the c-erbβ-2 Protein Enhances the Cytotoxicity ofcis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines,” Cancer Res., 51:4575-4580, 1991.
Hines et al., “Coexpression of c-kit and stem cell factor in breast cancer results in enhanced sensitivity to members of the EGF family of growth factors,” Breast Cancer Research and Treatment 58: 1-10, 1999.
Hines, et al., “Coexpression of the c-kit and Stem Cell Factor Genes in Breast Carcinomas,” Cell Growth & Differentiation, 6:769-779, 1995.
Hortobagyi, “High-Dose Chemotherapy for Primary Breast Cancer: Facts Versus Anecdotes,” J. Clin. Oncol., 17:25-29, 1999.
Kuerbitz et al., “Wild-type p53 is a cell cycle checkpoint determinant following irradiation,” Proc. Natl. Acad. Sci. USA, 89:7491-95, 1992.
Kwok and Sutherland, “Epidermal Growth Factor Reduces Resistance to Doxorubicin,” Int. J. Cancer, 49:73-76, 1991.
Kwok and Sutherland, “Enhancement of Sensitivity of Human Squamous Carcinoma Cells to Radiation by Epidermal Growth Factor,” J. Natl. Cancer Inst., 81:1020-24, 1989.
Lane, “p53, guardian of the genome,” Nature, 358:15-16, 1992.
Li et al., “PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer,” Science 275:1943-47, 1997.
Liaw et al., “Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome,” Nat. Genet., 16:64-67, 1997.
Liu et al., “Regulation of p21WAF1/CIP1Expression through Mitogen-activated Protein Kinase Signaling Pathway,” Cancer Res., 56:31-35, 1996.
Luo et al., “Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1,”Nature, 375:159-61, 1995.
Mendelsohn, “The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies,” Semin. Cancer Biol., 1:339-44, 1990.
Natali et al., “Breast cancer is associated with loss of the c-kit oncogene product,” Int. J. Cancer, 52:713-717, 1992.
Nelen et al., “Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease,” Hum. Mol. Genet., 6:1383-87, 1997.
Pietras et al., “Antibody to HER-2
eu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells,” Oncogene, 9:1829-38, 1994.
Shak, “Overview of the Trastuzumab (Herceptin) Anti-HER2 Monoclonal Antibody Clinical Program in HER2-Overexpressing Metastatic Breast Cancer,” Semin. Oncol., 26:71-77, 1999.
Sliwkowski et al., “Nonclinical Studies Addressing the Mechanism of Action of Trastuzumab (Herceptin),” Semin. Oncol., 26:60-70, 1999.
Vincent et al., “Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts,” Cancer Chemother. Pharmacol., 45:231-38, 2000.
Yarden et al., “Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand,” EMBO J. 6:3341-3351, 1987.
Winter-Vann Am et al., “Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate,” Proc. Natl. Acad. Sci. USA 100(11):6529-6534, May 27, 2003.
West et al., “Activation of the PI3K/Akt pathway and chemotherapeutic resistance,” Drug Resist Updat. 5(6):234-248, Dec. 2002.
Rusnak et al., “The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo,” Mol. Cancer Ther. 1:85-94, Dec. 2001.
DeMatteo, “The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571),” Ann. Surg. Oncol. 9(9):831-839, Nov. 2002.
Stal et al., “Akt kinases in breast cancer and the results of adjuvant therapy,” Breast Cancer Res. 5:R37-R44, 2003.
Glaspy, “Clinical applications of stem cell factor,” Curr. Opin. Hematol. 3(3):223-229, May 1996.
Krystal et al., “The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth,” Clin. Cancer Res. 6:3319-3326, Aug. 2000.
Hassan et al., “Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis,” Acta Haematol. 95(3-4):257-262, 1996.
Radosevic et al., “Cell cycle regulatory protein expression in fresh acute myeloid leukemia cells and after drug exposure,” Leukemia 15(4):559-566, Apr. 2001.
Nio et al., “Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas,” Anticancer Drugs 14(4):313-319, Apr. 2003.
Pertussini et al., “investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination therapy,” Blood 97(3)638-644, Feb. 1, 2001.
Kausch et al., “Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscule cells,” Biochem Biophys. Res. Cummun. 280(3):664-674, Jan. 26, 2001.
Ciocca et al., “Molecular markers for predicting response to tamoxifen in breast cancer,” Endocrine 13(1):1-10, Aug. 2000.
Bacus et al., “AKT2 is frequently upregulated in HER-2
eu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival,” Oncogene 21(22):3532-3540, May 16, 2002.
Beck et al., “Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors,” Blood 86(8)
Canella Karen A.
McDonnell Boehnen & Hulbert & Berghoff LLP
Ventana Medical Systems, Inc.
LandOfFree
Method and quantification assay for determining... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and quantification assay for determining..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and quantification assay for determining... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981328